MSc MD - Invivyd Chief Officer
| IVVD Stock | USD 0.70 0.07 9.09% |
Insider
MSc MD is Chief Officer of Invivyd
| Address | 1601 Trapelo Road, Waltham, MA, United States, 02451 |
| Phone | 781 819 0080 |
| Web | https://invivyd.com |
Invivyd Management Efficiency
The company has return on total asset (ROA) of (0.5356) % which means that it has lost $0.5356 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9656) %, meaning that it created substantial loss on money invested by shareholders. Invivyd's management efficiency ratios could be used to measure how well Invivyd manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.91. In addition to that, Return On Capital Employed is expected to decline to -1.22. At present, Invivyd's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.01, whereas Non Current Assets Total are forecasted to decline to about 3.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jared Allenbach | Recursion Pharmaceuticals | N/A | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Kelly Schick | C4 Therapeutics | 44 | |
| Jamie MD | Unity Biotechnology | 66 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
| Shafique MD | Recursion Pharmaceuticals | 53 | |
| Margo Mosley | Exscientia Ltd ADR | N/A | |
| Elizabeth Buck | Black Diamond Therapeutics | 49 | |
| David MD | Erasca Inc | 40 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Esq JD | Generation Bio Co | N/A | |
| Anirvan Ghosh | Unity Biotechnology | 60 | |
| CPA CPA | Atea Pharmaceuticals | 55 | |
| Blake Borgeson | Recursion Pharmaceuticals | 42 | |
| Matthew Stanton | Generation Bio Co | 51 | |
| Simona King | Passage Bio | 52 | |
| Scott Santiamo | Abeona Therapeutics | N/A | |
| Ryan Kelly | Recursion Pharmaceuticals | N/A | |
| JD Esq | Black Diamond Therapeutics | 59 | |
| JeanPierre Sommadossi | Atea Pharmaceuticals | 68 | |
| Maria MD | Atea Pharmaceuticals | 56 | |
Management Performance
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.54 |
Invivyd Leadership Team
Elected by the shareholders, the Invivyd's board of directors comprises two types of representatives: Invivyd inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Invivyd. The board's role is to monitor Invivyd's management team and ensure that shareholders' interests are well served. Invivyd's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Invivyd's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Laura Walker, CoFounder Officer | ||
| Elham PharmD, Chief Officer | ||
| Peter MD, Chief Officer | ||
| Robert Allen, Chief Officer | ||
| Jill JD, Chief Secretary | ||
| Mark Wingertzahn, Senior Affairs | ||
| Timothy Lee, Chief Officer | ||
| Jeremy Gowler, Chief Officer | ||
| Kyra Faircloth, Advocacy Affairs | ||
| Frederick Driscoll, Principal CFO | ||
| Rebecca Dabora, Chief Officer | ||
| MD MS, Chief Officer | ||
| Stacy MS, Chief Officer | ||
| Julie MBA, Senior Resources | ||
| MBA Duke, Chief Officer | ||
| David MBA, CEO Director | ||
| Heidi MS, VP CEO | ||
| MSc MD, Chief Officer | ||
| Scott Young, Senior Communications |
Invivyd Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Invivyd a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.54 | ||||
| Operating Margin | (21.75) % | ||||
| Current Valuation | (21.34 M) | ||||
| Shares Outstanding | 119.62 M | ||||
| Shares Owned By Insiders | 18.16 % | ||||
| Shares Owned By Institutions | 79.24 % | ||||
| Number Of Shares Shorted | 8.27 M | ||||
| Price To Book | 1.01 X | ||||
| Price To Sales | 37.06 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Invivyd is a strong investment it is important to analyze Invivyd's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Invivyd's future performance. For an informed investment choice regarding Invivyd Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Invivyd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Invivyd Stock refer to our How to Trade Invivyd Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Invivyd. If investors know Invivyd will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Invivyd listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share 0.02 | Return On Assets (0.54) | Return On Equity (0.97) |
The market value of Invivyd is measured differently than its book value, which is the value of Invivyd that is recorded on the company's balance sheet. Investors also form their own opinion of Invivyd's value that differs from its market value or its book value, called intrinsic value, which is Invivyd's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Invivyd's market value can be influenced by many factors that don't directly affect Invivyd's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Invivyd's value and its price as these two are different measures arrived at by different means. Investors typically determine if Invivyd is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Invivyd's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.